Prescription medicine
Perfluorohexyloctane Brand names: Miebo
Perfluorohexyloctane (Miebo) is a prescription medicine with an FDA approval on record since 2023. No generic is listed; pharmacies paid $263.57 per mL (Miebo 100% eye drop) in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the perfluorohexyloctane FDA label on DailyMed (effective March 10, 2026, Bausch & Lomb Incorporated); the NDA 216675 record on Drugs@FDA; every perfluorohexyloctane label on DailyMed.
Highlights of the record
FDA label of March 10, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageMIEBO ® (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease (DED).
Forms and strengths
- 1 mg
Solution.
On the market
- Earliest approval on file
- May 18, 2023 Miebo, Bausch And Lomb Inc; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- June 21, 2037 Miebo solution/drops; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $263.57 per mL Miebo 100% eye drop
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 1,914 through July 30, 2026
What is perfluorohexyloctane used for?
From the label: indications and usageMIEBO ® (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease (DED). MIEBO (perfluorohexyloctane ophthalmic solution) is a semifluorinated alkane indicated for treatment of the signs and symptoms of dry eye disease.
FDA pharmacologic class: Semifluorinated Alkane.
Source: FDA drug label (MIEBO), Bausch & Lomb Incorporated, effective March 10, 2026 (SPL set 6b283c02-7df4-4c00-951b-555cddffe77c), via openFDA; the full label on DailyMed
Is there a generic for perfluorohexyloctane (Miebo)?
No generic perfluorohexyloctane is approved (Drugs@FDA, October 8, 2026).
The Orange Book lists 10 patents for Miebo solution/drops, the last expiring on June 21, 2037. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2023 earliest approval on file
- 2037 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for perfluorohexyloctane (Miebo)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $263.57 per mL (Miebo 100% eye drop), up 3% from $256.05 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Miebo 100% eye drop (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Miebo 100% eye drop | Brand | $263.57 per mL | n/a | +3% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What do FAERS reports show for perfluorohexyloctane?
The FDA Adverse Event Reporting System holds 1,914 reports that list perfluorohexyloctane among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 111 are coded as a death and 170 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Perfluorohexyloctane side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other